Enterprise Value

4.871B

Cash

48.46M

Avg Qtr Burn

N/A

Short % of Float

2.32%

Insider Ownership

57.00%

Institutional Own.

31.71%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
PEMRYDI RTU® Details
Small cell lung cancer, Malignant pleural/peritoneal mesothelioma

Approved

Update

Lisdexamfetamine Dimesylate Details
Attention deficit hyperactivity disorder

Approved

Quarterly sales

RELEUKO® (filgrastim-ayow) Details
Chemotherapy-induced neutropenia

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

IPX203 Details
Parkinson's disease

NDA

Acceptance for review